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Background: Malaria in pregnancy increases the risk of maternal anemia, abortion and low birth weight.
Approximately 85.3 million pregnancies occur annually in areas with Plasmodium falciparum transmission.
Pregnancy has been reported to alter the pharmacokinetic properties of many anti-malarial drugs. Reduced drug
exposure increases the risk of treatment failure. The objective of this study was to evaluate the population
pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin in pregnant women with
uncomplicated P. falciparum malaria in Uganda.
Methods: Twenty-one women with uncomplicated P. falciparum malaria in the second and third trimesters of
pregnancy received the fixed oral combination of 80 mg artemether and 480 mg lumefantrine twice daily for three
days. Artemether and dihydroartemisinin plasma concentrations after the last dose administration were quantified
using liquid chromatography coupled to tandem mass-spectroscopy. A simultaneous drug-metabolite population
pharmacokinetic model for artemether and dihydroartemisinin was developed taking into account different
disposition, absorption, error and covariate models. A separate modeling approach and a non-compartmental
analysis (NCA) were also performed to enable a comparison with literature values and different modeling strategies.
Results: The treatment was well tolerated and there were no cases of recurrent malaria. A flexible absorption
model with sequential zero-order and transit-compartment absorption followed by a simultaneous
one-compartment disposition model for both artemether and dihydroartemisinin provided the best fit to the data.
Artemether and dihydroartemisinin exposure was lower than that reported in non-pregnant populations. An
approximately four-fold higher apparent volume of distribution for dihydroartemisinin was obtained by
non-compartmental analysis and separate modeling compared to that from simultaneous modeling of the drug
and metabolite. This highlights a potential pitfall when analyzing drug/metabolite data with traditional approaches.
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Conclusion: The population pharmacokinetic properties of artemether and dihydroartemisinin, in pregnant women
with uncomplicated P. falciparum malaria in Uganda, were described satisfactorily by a simultaneous
drug-metabolite model without covariates. Concentrations of artemether and its metabolite dihydroartemisinin
were relatively low in pregnancy compared to literature data. However, this should be interpreted with caution
considered the limited literature available. Further studies in larger series are urgently needed for this vulnerable
group.
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MalariaBackground
Malaria is a major cause of morbidity and mortality in
pregnancy [1]. An estimated 85.3 million pregnancies
occurred in 2007 in areas with Plasmodium falciparum
transmission [2]. The susceptibility to malaria is
increased during pregnancy as a result of immunological
and hormonal changes [3,4]. P. falciparum malaria in
pregnancy is associated with increased anaemia and a
higher risk of severe malaria and death compared to a
non-pregnant adult population [5]. Parasitized erythro-
cytes accumulate in the placenta [3,6,7]. Malaria reduces
birth weight through intrauterine growth retardation
and preterm delivery [8].
Pregnancy has been reported to alter the pharmacoki-
netic properties of many anti-malarial drugs. Lower drug
exposure in pregnant women has previously been
reported for artemether/dihydroartemisinin [9], artesu-
nate/dihydroartemisinin [10], dihydroartemisinin [11],
lumefantrine [12], atovaquone [13], proguanil [13], sul-
phadoxine [14] and pyrimethamine [15]. This may in-
crease the risk of treatment failure, particularly when
immune responses to malaria are suppressed during
pregnancy. In contrast some studies show similar (e g,
pyrimethamine, amodiaquine and desethylamodiaquine)
or higher (e g, pyrimethamine, sulphadoxine and meflo-
quine) anti-malarial drug exposure in pregnant women
compared to the non-pregnant adult patient population
[14-20]. Different pharmacokinetic analytical methodolo-
gies, such as non-compartmental analysis (NCA), separ-
ate and simultaneous population pharmacokinetic
analysis, have been employed which further complicates
the interpretation. Comparison of parameter estimates
obtained with different methodologies should be per-
formed with caution.
Artemisinin-based combination therapy (ACT) is
recommended as first-line treatment by the World
Health Organization (WHO) for uncomplicated P. fal-
ciparum malaria [1]. The fixed oral combination of arte-
mether and lumefantrine is one of the most widely used
ACTs and gives high cure rates (>95%) and good toler-
ability in children and adults with uncomplicated P. fal-
ciparum malaria [21-23]. However, unacceptably lowcure rates were reported for pregnant women (n = 124)
on the north-west border of Thailand (PCR-corrected
cure rate of 82.0% (95% CI. 74.8-89.3) at delivery or day
42 if later) with a standard fixed combination explained
by low drug concentrations in late pregnancy [12,24].
On the other hand, high efficacy (PCR-corrected cure
rate of 98.2% (95% CI. 93.5-99.7) at delivery or day 42 if
later) was reported in pregnant women in Uganda
(n = 152) when treated with a standard regimen of arte-
mether and lumefantrine [25]. Transmission, and there-
fore immunity, is substantially higher in Uganda than in
Thailand, but pharmacokinetic differences may also con-
tribute to these findings.
The objective of this study was to characterize the
population pharmacokinetic properties of artemether
and its metabolite dihydroartemisinin in pregnant




This pharmacokinetic study was nested into a larger effi-
cacy study conducted in the Mbarara National Referral
Hospital (MNRH) antenatal clinic (ANC) in Uganda.
Full clinical details are reported elsewhere [25]. Ethical
approval was obtained from the Mbarara University Fac-
ulty of Medicine Research and Ethics Committee, the
Mbarara University Institutional Ethics Committee, the
Uganda National Council for Science and Technology
(ethics committee) and the de Protection des Personnes
de St. Germain en Laye, lle de France XI. The trial was
registered at ClinicalTrials.gov (NCT00495508). The
patients were recruited from March to September 2008.
Inclusion criteria were P. falciparum mixed- or mono-
infection (detected by microscopy), residence in the
Mbarara municipality (radius 15 km from MNRH) and
an estimated gestation age (EGA) of at least 13 weeks.
Exclusion criteria were P. falciparum parasitaemia above
250,000 parasite/μL, severe anaemia (Hb <7 g/dL), signs
or symptoms of severe malaria requiring parental treat-
ment, known allergy to artemisinin derivates, lumefan-
trine or quinine, previous participation in the efficacy
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schedule. Patients were enrolled if they fulfilled all of the
inclusion criteria, none of the exclusion criteria, and if
written informed consent was obtained. The presented
population pharmacokinetic analysis was conducted
using the dense artemether/dihydroartemisinin samples.
Dose regimen and blood samples
Four tablets of the fixed oral combination of artemether
and lumefantrine (CoartemW Novartis Pharma AG, Basel,
Switzerland; each tablet contained 20 mg artemether and
120 mg lumefantrine) were administered twice daily for
three days (0, 8, 24, 36, 48 and 60 hours) with 200 mL of
milk tea at each dose to optimize the oral bio-availability
of lumefantrine [26]. A full replacement dose was given if
the dose was vomited within 30 min and a half replace-
ment dose was given if the dose was vomited between
30 min and one hour. The patient was withdrawn from
the study and treated with rescue treatment if the replace-
ment dose was vomited again within 30 min. Venous
blood samples (2 mL) were drawn from a cannula into
heparinized tubes at 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2,
2.5, 3, 4, 6, 8, and 10 hours after the last dose.
Drug analysis
Blood samples were centrifuged at 1,400 g for 5 min and
plasma was stored at -70°C until analysis. Plasma sam-
ples were shipped on dry ice to MORU Clinical Pharma-
cology Laboratory, Bangkok, Thailand for drug
quantification. Quantification of artemether and dihy-
droartemisinin was performed by a previously published
method [27]. Artemether and dihydroartemisinin and
their stable isotope labeled internal standards were
extracted from plasma using solid phase extraction
(HLB u-elution SPE 96-well plate, Waters, USA) sepa-
rated and quantified by liquid chromatography (Agilent
1200 system, Agilent Technologies, USA) coupled to
positive electro spray tandem mass spectroscopy (API
5000 triple quadrupole, Applied Bios stems/MDS SCIEX,
USA). To ensure precision and accuracy during quantifi-
cation, triplicates of quality control samples at three
concentrations; 3.46 ng/ml, 36.0 ng/ml and 375 ng/ml
for both artemether and dihydroartemisinin were ana-
lyzed with every batch. The overall accuracy (i e, relative
standard deviation) was less than 5.4%. The limit of de-
tection (LOD) was set to 0.5 ng/mL and the lower limit
of quantification (LLOQ) was set to 1.43 ng/mL for both
compounds. The MORU laboratory is a participant in
the QA/QC programmed supported by the Worldwide
Antimalarial resistance Network (WWARN).
Compartmental analysis
Artemether and dihydroartemisinin dose and plasma con-
centrations were converted into molar units and modeledas the natural logarithm of the molar plasma concentra-
tions. Modeling and simulation was performed on a Win-
dows XP operating system (Microsoft Corporation,
Seattle, WA, USA) with a G95 Fortran compiler (Free
Software Foundation, Boston, MA, USA) using NON-
MEM v.7.1 (ICON Development Solutions, Ellicott City,
MD, USA). ADVAN5, TRANS1 and the first order condi-
tional estimation method with interaction was used during
model building [28]. Post-processing and automation was
performed using Pearl-Speaks-NONMEM (PsN) v. 3.2.12
[29,30], Census v. 1.2b2 [31], Xpose v. 4 [32] and R v.
2.10.1 (The R Foundation for Statistical Computing).
The objective function value (OFV) computed as
minus twice the log likelihood of the data, physiological
plausibility and goodness-of-fit diagnostics were used to
evaluate competing models during the model building
process. A reduction in OFV of 3.84 or more was con-
sidered a significant (p = 0.05) improvement after the
introduction of one new parameter (one degree of
freedom).
Pharmacokinetic properties of artemether and dihy-
droartemisinin were modeled both separately and simul-
taneously using a one-compartment disposition model
with first-order absorption and elimination for both arte-
mether and dihydroartemisinin. Complete conversion of
artemether into dihydroartemisinin was assumed for all
modeling approaches [33,34]. The population pharmaco-
kinetic models were parameterized using a first-order
absorption rate constant (ka), artemether elimination
clearance (CLARM/F), apparent artemether volume of
distribution (VARM/F), dihydroartemisinin elimination
clearance (CLDHA/F), and apparent dihydroartemisinin
volume of distribution (VDHA/F). Inter-individual vari-
ability (IIV) was implemented exponentially for all
parameters.
The simultaneous population pharmacokinetic base
model was optimized further in order to describe accur-
ately the pharmacokinetic properties of artemether and
dihydroartemisinin. The implementation of relative bio-
availability was investigated followed by addition of one
and two peripheral distribution compartments for both
artemether and dihydroartemisinin. Enterohepatic recir-
culation of artemether was evaluated by applying a model
event time (MPAST) to the rate constant from a periph-
eral compartment to the central compartment. This gen-
erated continuous flow from the central compartment to
a hypothetical biliary compartment and a time-dependent
backflow to the gut compartment mimicking the entero-
hepatic circulation. A semi-mechanistic liver model struc-
ture described by Gordi et al was also applied to the data
in order to describe partial pre-systemic conversion of
artemether into dihydroartemisinin [35].
Several absorption models were evaluated in combin-
ation with the most appropriate body structure; first-
Table 1 Demographic information of the study
population
Mean ± S.D. Median (range)
Number of patients 21
Total artemether dose (mg/kg) 8.46 ± 1.22 8.73 [5.46-9.80]
Total number of samples 316
Sample size (samples/patient) 15.0 ± 0.805 15 [12-16]
covariates
Body weight (kg) 58.1 ± 10.1 55 [49-88]
Age (years) 21.4 ± 4.28 21 [16-35]
Gestational age (weeks) 25.8 ± 7.77 27 [13-36]
Haemoglobin (g/dL) 11.1 ± 1.72 11.3 [7.6-14.6]
Red blood cell count (106 cells/
cmm)
3.74 ± 0.629 3.71 (2.37-4.79)
Haematocrit (%) 33.7 ± 5.14 34.0 (23.2-44.5)
Neutrophils (counts/μL) 2.73 ± 0.802 2.75 (1.14-4.13)
Eosinophils (counts/μL) 0.130 ± 0.148 0.0700 [0.0200-
0.570]
Basophils (counts/μL) 0.0280 ± 0.0140 0.0200 [0.0100-
0.0600]
Lymphocytes (counts/μL) 2.08 ± 0.667 1.98 [1.12-3.51]
Monocytes (counts/μL) 0.590 ± 0.214 0.550 [0.260-1.00]
Platelets (103/cmm) 166± 62.0 167 [64-285]
Alanine aminotransferase
(IU/L)
16.1 ± 6.77 14.0 [5.00-35.0]
Creatinine (mg/dl) 0.481 ± 0.103 0.470 [0.330-0.660]
Bilirubin (mg/dl) 1.24 ± 1.10 0.910 [0.560-5.53]
Diastolic blood pressure (mmHg) 60.1 ± 6.20 60.0 [46.0-75.0]
Temperature (°C) 36.8 ± 0.747 36.7 [36.0-38.5]
P. falciparum parasitaemia
(parasites/μL)
10900± 32000 1570 [88.0-148000]
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zero-order and zero order absorption followed by first-
order absorption with and without lag-time. An alter-
native way to describe partial pre-systemic conversion
of artemether into dihydroartemisinin was also consid-
ered by an estimated ratio of dual first order absorption
of artemether and dihydroartemisinin. A transit-
compartment absorption model with an individually
estimated number of transit compartments was tried
and compared to a less flexible transit-compartment
absorption model where the number of transit-
compartments (1-10) was evaluated and fixed for the
population. A semi-mechanistic transit-compartment
absorption model was also evaluated combining zero-
order dissolution of the drug before drug absorption
via a fixed number of transit compartments. A correl-
ation matrix of more than 50% between variability
components was considered as a significant contribu-
tion. Additive, proportional and intercept-slope error
models were evaluated to explain residual random vari-
ability of artemether and dihydroartemisinin. Separate
and combined error models for artemether and dihy-
droartemisinin were evaluated.
Different methodologies to avoid bias in parameter esti-
mates caused by multiple samples being below the limit of
quantification (BLOQ) were evaluated [36-38]. BLOQ data
were imputed by a fixed concentration at LLOQ/2 or
modeled as censored data using the M3 method [36-38] in
combination with Laplacian estimation.
All covariates (Table 1) were screened by adding
them individually on each of the pharmacokinetic
parameters in the model using a linear and an expo-
nential relationship. Significant covariates (p < 0.05,
ΔOFV > 3.84) that were considered physiologically
plausible were evaluated through forward addition and
backward elimination covariate selection (SCM,
[29,39]). A p-value of 0.05 was used in the forward step
and a p-value of 0.01 (ΔOFV > 6.63) was considered
significant for retaining a covariate in the model during
the backward elimination. Body weight was also evalu-
ated as an allometric function on all clearance and vol-
ume parameters. A model with estimated age of
gestation as a covariate on CLARM, VARM, CLDHA,
VDHA, and MTT in a linear relationship was evaluated
for a full-covariate model approach.
Eta and epsilon shrinkage was calculated to assess the
reliability of individual parameter estimates and good-
ness-of-fit diagnostics [40]. A non-parametric bootstrap
of 1,000 datasets was performed in order to calculate
non-parametric confidence intervals. The predictive
power of the model was examined by visual and numer-
ical predictive checks, using 2,000 simulations of each
individual plasma concentration series [41]. The 95%
confidence intervals of the simulated 5th, 50th and 95thpercentile were overlaid with the 5th, 50th and 95th per-
centile of the observed data.Non-compartmental analysis
Individual concentration-time data were analyzed with
NCA using WinNonlin v. 5.3 (Pharsight Corporation,
California, USA). Complete in vivo conversion of arte-
mether into dihydroartemisinin was assumed [42]. The
dose of dihydroartemisinin was calculated using the rela-
tive difference in molecular weight of artemether and
dihydroartemisinin [dosedihydroartemisinin = doseartemether ×
(MWdihydroartemisinin: 284.3 g/mol)/(MWartemether: 298.4 g/
mol)]. Total exposure up to the last measured concentra-
tion (AUC0-LAST) was calculated using the linear trapez-
oidal method for ascending concentrations and the
logarithmic trapezoidal method for descending concentra-
tions. Extrapolation from the last observed concentration
was performed using CLAST/λZ for each individual subject.
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elimination half-life using the observed concentrations in
the terminal elimination phase. Maximum concentration
(CMAX) and time to CMAX (TMAX) were taken directly
from the observed data. Standard procedures in WinNon-
lin were used to compute the individual values for appar-
ent volume of distribution (VZ/F) and oral elimination
clearance (CL/F).
Pharmacokinetic parameter estimates from the NCA
and separate modeling were compared to that produced
by a simultaneous modeling strategy. Small but system-
atic differences in individual parameter estimates might
result in significant differences between methodologies,
when using paired tests, but will be of no clinical rele-
vance. A student t-test was therefore used to compare
logarithmically transformed parameter estimates between
two methodologies. ANOVA with regression analysis was
performed to compare logarithmically transformed par-
ameter estimates between more than two methodologies.
Results
Demographic information
Twenty-one (21) pregnant women in their second and
third trimesters from Uganda were enrolled in the study
(Table 1). The treatment was well tolerated and no cases
of vomiting or recurrent malaria infections were recorded.
Pharmacokinetic analysis
Compartmental analysis of artemether and
dihydroartemisinin
A zero-order absorption followed by transit compartment
absorption described the artemether and dihydroartemisi-
nin absorption better than all other absorption models
(ΔOFV> -71). The administered drug disintegrates in the
gut, resulting in a continuous drug supply, described by a
zero-order process followed by transit absorption of drug
into the systemic circulation. Six transit compartments
were sufficient to describe the data. Other absorption
models were not better and/or produced unreliable par-
ameter estimates (RSE> 50%). The implementation of a
pre-systemic artemether elimination pathway in the model
(ΔOFV= -12.5) was only possible in combination with a
two-compartment disposition of artemether and the M3
method, but this resulted in an unrealistic artemether
elimination half-life of 48.8 h [46.7-53.1] so this model
structure was not considered as superior.
A simultaneous one-compartment drug-metabolite
model best described the disposition pharmacokinetics
of artemether and dihydroartemisinin. Goodness-of-fit
diagnostics of the final model showed an adequate
description of observed data (Figure 1). The under-
prediction of low artemether and dihydroartemisinin
concentrations is a direct consequence of a high propor-
tion of data below the LLOQ. The goodness-of-fitdiagnostics in the present study (Figure 1) suggested that
a two-compartment disposition model for dihydroarte-
misinin might be a better description of the data but the
addition of a peripheral compartment for dihydroartemi-
sinin did not improve the model fit (ΔOFV= 0.003). An-
other study in children (one to 10 years old) with
uncomplicated P. falciparum malaria in Tanzania was best
described by a simultaneous artemether-dihydroartemisinin
model consisting of two- and one-disposition compart-
ments for artemether and dihydroartemisinin, respectively
[33]. The addition of a peripheral compartment for arte-
mether improved the model fit (ΔOFV= -14.8) but could
not be retained due to a combination of poor precision
(RSE>30%) in additional parameters and misspecification
of censored data. Implementation of the M3 method solved
the misspecification of censored data but poor parameter
precision (RSE>30%) remained. Incorporation of inter-
individual variability in the relative bioavailability signifi-
cantly improved the model fit (ΔOFV= -133) due to vari-
able absorption of artemether.
A combined additive error model for both the drug
and the metabolite was sufficient to describe the random
residual variability in the data. This is not unexpected
since artemether and dihydroartemisinin plasma samples
were obtained from the same blood sample and concen-
trations were quantified using a simultaneous bioanalyti-
cal method.
In the final model, the absorption rate constant was
set to be identical to the rate constant between transit
compartments because of the poor precision of the ab-
sorption rate constant (RSE > 50%). IIV for the distribu-
tion volume of artemether and dihydroartemisinin were
fixed to zero because of poor precision (RSE > 50%). In-
corporation of relative bioavailability should theoretically
decorrelate pharmacokinetic parameters (i e, clearance
and volume parameters) within a patient. As expected,
variability components between these parameters were
not correlated (<50% correlation) in the final model.
The relatively short half-life of artemether and dihy-
droartemisinin can cause a bias in parameter estimates be-
cause a large proportion of concentration measurements
below the LLOQ (i.e. 14.9% and 47.6% of artemether and
13.7% and 33.3% of dihydroartemisinin samples were
below the LLOQ in total and at 10 hours after dose, re-
spectively). Coding BLOQ data as missing data performed
well with no trends of over- or under-predicting BLOQ
data (Figure 2). Incorporation of the M3 method or im-
puting BLOQ data with LLOQ/2 resulted only in minor
improvements in the visual diagnostics. The M3 and
LLOQ/2 approach resulted in much higher condition
numbers compared to the conventional method of coding
BLOQ data as missing data, which implies that these
models are less robust. BLOQ data were therefore coded
as missing data in the final model.
Figure 1 Artemether and dihydroartemisinin goodness-of-fit. The solid black line represents the line of identity, the local polynomial
regression fitting for observations predicted above LLOQ is represented by the dashed black line and the local polynomial regression fitting for
all observations is represented by the grey dashed line. The horizontal and vertical dashed black lines represent the lower limit of quantification
(LLOQ). Clinical observations are represented by the black circles. Percentages mentioned in the diagnostic plots represent the percentages of the
total amount of data in the particular subset.
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study. Artemether is predominantly metabolized by
cytochrome 3A4 [43] and dihydroartemisinin by UGT
1A9 and UGT 2B7 [44]. Both the hepatic and intestinal
CYP 3A4 activities have been reported to be induced
during pregnancy compared with post-partum women
[45,46]. Between the second and third trimester of preg-
nancy no difference in CYP 3A4 activity has been
observed [45]. This might explain why no covariate ef-
fect of estimated age of gestation could be found on
artemether elimination clearance in this study. DHA is
eliminated via glucuronidation and limited evidence sug-
gests higher UGT 1A9 and UGT2B7 activities at the
time of delivery compared with non-pregnant women
[47,48]. However, no covariate effect of estimated age of
gestation was found on dihydroartemisinin elimination
clearance either. This might indicate that there is no dif-
ference in UGT 1A9 and UGT2B7 activity between the
second and third trimester. As there was no non-pregnant
control group, pregnancy could not be evaluated as a cat-
egorical covariate in this study. A full covariate approach
was applied to enable a visual inspection of the estimated
age of gestation effect on CLARM/F, VARM/F, CLDHA/F,
VDHA/F and MTT (Figure 3). The covariate effect was dis-
tributed with a certainty of 95% between -7.0% and 5.5%
change in parameter estimate per estimated age of gesta-
tion in weeks, confirming the absence of significantcovariate effects from estimated age of gestation in the
studied population.
The numerical predictive check of the final model
computed 1.11% (95% CI. 0.74 to 11.11%) and 2.96%
(95% CI, 0.74-11.85%) of the observed artemether con-
centrations below and above the 90% prediction inter-
val, respectively. For dihydroartemisinin 0% and 0.37%
(95% CI. 0.37-12.45%) of observations were calculated
below and above the 90% prediction interval, respect-
ively. This indicated an over-prediction of the variabil-
ity from both the drug and the metabolite. This was a
result of problems with fitting the erratic absorption
phase and a relatively small study population (Figure 2).
No cases of vomiting were reported nor were there
other possible explanations for the observed absorption
characteristics such as concomitant therapy. Similar er-
ratic absorption profiles have been reported previously
in healthy volunteers [49] and similar over prediction
was reported in children with uncomplicated malaria
in Tanzania [33].
The central tendencies of the concentration-time pro-
files are predicted adequately and population parameter
estimates were robust but showed large inter-individual
variability as indicated by the predictive checks (Table 2
and Figure 2). All shrinkage estimates were below 20%
indicating the reliability of the individual parameter
estimates.
Figure 2 Visual Predictive Check of plasma artemether and dihydroartemisinin concentrations. Upper panel: open circles represent the
observed data, the solid lines the 5th, 50th and 95th percentiles of the observed data and the shaded area the 95% confidence intervals
of the 5th, 50th and 95th percentiles of the simulated plasma concentrations (nmol/L). The limit of quantification is represented by the
black dashed line. Lower panel: the shaded area represents the simulated 95% confidence intervals for the fraction of BQL data. The
black solid line represents the observed fraction of BQL data.
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Percent change per week of gestational age
Figure 3 Boxplots (2.5 - 97.5 percentiles) visualising the effect
of estimated gestational age on pharmacokinetic parameters.
Mean transit time (MTT), apparent volume of distribution
dihydroartemisinin (VDHA/F), elimination clearance (CLDHA/F),
apparent volume of distribution artemether (VARM/F) and elimination
clearance artemether (CLARM/F) from 250 bootstrap runs.
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Due to the absence of a non-pregnant control group the
results had to be compared to literature. The majority of
the pharmacokinetic evaluations of artemether and dihy-
droartemisinin have been performed using NCA
[9,10,42]. The standard procedure of analyzing a metab-
olite is to adjust the input dose for the metabolite by the
relative difference in molecular weight between the par-
ent drug and the metabolite. The metabolite is then
assumed to be absorbed from the gut into the systemic
circulation. This is inaccurate since the drug in most
cases is absorbed as parent drug and then converted to
metabolite in vivo. The same assumption is made when
analyzing the data using a separate pharmacokinetic
drug and metabolite model. These approaches might re-
sult in non-physiological parameter estimates for the
metabolite when analyzing the data both with NCA or
separate modeling. A simultaneous pharmacokinetic
drug-metabolite model will therefore produce more ac-
curate and physiologically plausible parameter estimates
for both the drug and the metabolite.
Table 2 Parameter estimates for the final simultaneous artemether and dihydroartemisinin model
Parameter Population estimatea 95% CIb IIV[%CV]a 95% CIb
(% RSE)b (% RSE)b
CLARM/F (L/hr) 875 (18.7) 625-1280 28.0 (47.6) 12.0-37.8
VARM/F (L) 2160 (17.4) 1620-3100 - -
CLDHA/F (L/hr) 468 (10.2) 387-588 90.4 (39.0) 40.5-126
VDHA/F (L) 57.1 (20.1) 41.7-88.8 - -
MTT (hr) 0.274 (19.4) 0.174-0.378 75.2 (39.6) 41.4-121
DUR (hr) 0.687 (25.5) 0.380-1.14 151 (24.1) 90.6-209
F 1 (fixed) - 85.5 (24.8) 53.2-108
No. of transit compartments 6 (fixed) - - -
σ 0.166 (6.87) 0.130-0.221 23.1 (51.7) 8.35-35.2
Post-hoc estimates parametersc Artemether Median (range) Dihydroartemisinin Median (range)
AUC60h-∞ (hr × ng/mL) 111 (16.2-317) 167 (55.3-437)
CMAX (ng/mL) 32.9 (7.5-82.8) 45.2 (14.1-114)
TMAX (hr) 1.16 (0.65-3.81) 1.37 (0.82-3.89)
aPopulation mean values and inter-individual variability (IIV) estimated by NONMEM. IIV is presented as 100* ((emean variance estimate)-1)1/2.
bThe relative standard error (RSE) is calculated as 100*(standard deviation/mean value) from 1,046 successful iterations of a non-parametric bootstrap. The 95%
confidence interval (95% CI) is displayed as the 2.5 to 97.5 percentiles of the bootstrap estimates.
cPost-hoc estimates were calculated as the median and ranges of the empirical Bayes estimates.
CLARM/F: elimination clearance of artemether, VARM/F: apparent volume of distribution of artemether, CLDHA/F: elimination clearance of dihydroartemisinin, VDHA/F;
apparent volume of distribution of dihydroartemisinin, MTT; mean transit time, DUR; duration of zero order-absorption and F; relative bioavailability. The additive
error (σ) variance will essentially be exponential on artithmic scale data. AUC: total area under the plasma concentration-time curve after the last dose, CMAX:
maximum concentration after the last dose and TMAX: Time to maximum concentration.
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http://www.malariajournal.com/content/11/1/293The observed data were evaluated using NCA and a
first-order absorption model followed by a separate one-
compartment disposition model for artemether and
dihydroartemisinin. Parameter estimates from these
approaches were compared to the results obtained using
a simultaneous artemether-dihydroartemisinin one-com-
partment disposition model with first-order absorption
to assess the impact of the different pharmacokinetic
analysis methodologies. All tested methodologies described
the data reasonably well (Table 3). Significant differencesTable 3 Summary of parameter estimates for a comparative a






CL/F (L/hr) 753 [220-7381] 904 [375-2919]
V/F (L) 1750 [547-11045] 1293 [1279-1301]
Ka (hr-1) - 0.392 [0.137-2.25]
AUC60h-LAST (hr × ng/ml) 98.5 [7.24-355] 86.4 [26.5-207]
Dihydroartemisinin
CL/F (L/hr) 381 [167-1364] 534 [220-1116]
V/F (L) 647 [374-4154] 691 [325-1699]
Ka (hr-1) - 0.472 [0.472-0.472
AUC60h-LAST (hr × ng/ml) 196 [53.2-449] 140 [67.2-340]
CL/F: elimination clearance, V/F: apparent volume of distribution, Ka: absorption con
after the last dose to the last sample time. P-values were presented from an ANOVA
transformed parameter estimates. Non-compartmental analysis (Approach 1), separin apparent volume of distribution and absorption rate
constant were evident when comparing NCA/separate
modeling to simultaneous modeling (Table 3). The arte-
mether absorption rate constant was approximately two
times higher using simultaneous modeling compared to
separate modeling. The artemether apparent volume of
distribution obtained with separate modeling was approxi-
mately 25% and 50% lower compared to the estimates
obtained with NCA and simultaneous modeling, respect-
ively. The effect on the metabolite was even larger with annalysis of different methodologies
Approach 3 P-value P-value P-value
ing Simultaneous modelling
Median [range]
(1 vs 2) (1 vs 3) (2 vs 3)
858 [365-4593] 0.975 0.899 0.972
2292 [951-4967] 0.002 0.826 0.013
0.878 [0.381-2.17] - - 0.008
91.1 [17.4-215] 0.989 0.999 0.983
496 [214-1199] 0.311 0.459 0.910
163 [97-200] 0.247 <0.001 <0.001
] - - - -
150 [62.2-345] 0.304 0.502 0.930
stant and AUC60h-LAST: total area under the plasma concentration-time curve
test with regression analysis or a student t-test (comparing 2 groups) on log
ate modelling (Approach 2) and simultaneous modelling (Approach 3) results.
Table 4 A comparison of the artemether pharmacokinetic properties to literature values
Artemether


























NCA in Thai pregnant
















NCA in Thai patients
(N = 25) [52]
Mean ± S.D. 2.64 ± 1.36 0.828 ± 0.679 2.0 (1.00-8.00) 2.20 ± 1.00 -
NCA in Thai patients
(N = 13) [54] c
Mean (range) 6.03 (3.21-10.23) 1.12 (0.73-1.50) 2.0 (2.0-2.0) 2.6 (1.8-4.7) 3.27
Healthy subjects NCA in Pakistani
subjects (N = 12) [42]d





subjects (N = 14) [53]
Mean ± S.D. 0.791 ± 0.906 0.343 ± 0.386 1.5 [1–4] 1.6 -
NCA in Caucasian
subjects (N = 8) [50]e
Mean ± S.D. 0.350 ± 0.300 0.190 ± 0.130 1.60 ± 0.800 0.500± 0.100 -
aMedian and ranges were derived from the empirical Bayes estimates.
bPopulation estimate (%RSE).
cAfter a single dose of 300 mg artemether and four consecutive 100 mg artemether doses daily.
dAfter a single dose of artemether-lumefantrine (Co-Artem).
eAfter five doses artemether mono-therapy.
AUC: area under the concentration-time curve, CMAX: maximum concentration, TMAX: time to maximum concentration and T1/2: elimination half-life. AUC and CMAX
were normalized by artemether dose.
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http://www.malariajournal.com/content/11/1/293approximately four times lower estimated apparent vol-
ume of distribution for dihydroartemisinin using simultan-







Final model (N = 21) Median (range)a 2.11
(0.70
NCA (N= 21) Median (range) 2.57
(0.69
NCA in Thai pregnant
patients (N = 13) [9]





NCA in Thai male
patients (N = 25) [52]
Mean ± S.D. 7.92
NCA in Thai
patients (N = 13) [54]c
Mean (range) 11.1
(7.04
Healthy subjects NCA in Pakistani




subjects (N = 14) [53]
Mean ± S.D. 2.51
NCA in Caucasian
subjects (N = 8) [50]e
Mean ± S.D. 2.42
aMedian and ranges were derived from the empirical Bayes estimates.
bPopulation estimate (%RSE).
cAfter a single dose of 300 mg artemether and four consecutive 100 mg artemethe
d After a single dose of artemether-lumefantrine (Co-Artem).
eAfter five doses artemether mono-theraphy.
AUC: area under the concentration-time curve, CMAX: maximum concentration, TMAX
were normalized by dihydroartemisinin dose.This shows clearly that the volume of distribution estimate
is affected by the actual absorption model for dihydroarte-


































± 3.40 2.69 ± 1.34 2.00
(1.00-6.00)
















± 1.22 0.982± 0.547 1.5 [1-4] 1.5 ± 0.6 -
± 0.682 0.818± 0.294 1.6 ± 0.8 0.8 ± 0.3 -
r doses daily.
: time to maximum concentration and T1/2: elimination half-life. AUC and CMAX
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and the distribution phases for the drug and metabolite.
Although the approaches led to significant differences in
pharmacokinetic parameter estimates, this may have little
clinical relevance. Total exposure of both artemether and
dihydroartemisinin were not significantly different for the dif-
ferent approaches. A trend of lower dihydroartemisinin ex-
posure after separate and simultaneous modeling compared
to after NCA was observed. This phenomenon resulted from
difficulties with fitting the erratic absorption phase.
Comparison to literature
Data collected in this study did not allow investigation
of auto-induction since patients were sampled only after
the last dose. However, a 57% increase in elimination
clearance of artemether with each dose (auto-induction)
has been suggested in a previous publication [33] and
lower artemether exposures were found after multiple
dosing [50-53]. The elimination clearance in this study
was 4.9-fold higher than that in healthy Pakistani volun-
teers when sampled after a single dose administration
(15.1 L/hr/kg vs 3.11 L/h/kg). This could be a result
of auto-induction. However, the effect of a different sam-
pling scheme, pregnancy, ethnic differences and/or dis-
ease should also be considered [42].
CMAX, AUC, TMAX, T1/2 and CL results obtained by
NCA and simultaneous population pharmacokinetic drug
metabolite modeling were compared to literature NCA
results in Tables 4 and 5. The elimination half-life of arte-
mether (1.96 h) is longer compared to the elimination
half-life of dihydroartemisinin (1.39 h), which suggests for-
mation rate limited elimination of dihydroartemisinin.
Therefore, the elimination half-life of dihydroartemisinin
obtained with compartmental modeling did not reflect its
physiological value as a result of flip-flop kinetics. Conse-
quently, the NCA elimination half-life for dihydroartemisi-
nin was considered as the true value.
Estimated artemether and dihydroartemisinin exposure
in this African pregnant woman population was similar to
that reported in pregnant Thai patients [9]. Both the
present study and the previously published study in Thai
pregnant women [9] showed lower artemether exposures
but in a similar range compared to one Thai adult non-
pregnant patient population [52]. In contrast, exposures
were considerably lower compared to another Thai, adult,
non-pregnant patient population [54]. Dihydroartemisinin
exposures in both African and Thai pregnant women were
lower compared to the two Thai adult non-pregnant pa-
tient populations [52,54]. This might suggest a lower arte-
mether and dihydroartemisinin exposure in a pregnant
population compared to a non-pregnant patient popula-
tion. However, this comparison was based on only two
available reference populations with different ethnicity
[52,54]. Therefore, studies in larger series with non-pregnant control groups are urgently needed to further as-
sess the pharmacokinetics of artemether and dihydroarte-
misinin in pregnant women.
Conclusion
In conclusion, the population pharmacokinetic proper-
ties of artemether and its metabolite dihydroartemisinin
were well described by a simultaneous drug-metabolite
model in 21 pregnant women with uncomplicated P. fal-
ciparum malaria in Uganda. Total exposure of arte-
mether and dihydroartemisinin were somewhat lower in
these pregnant women compared to literature adult pa-
tient populations. However, these results should be
interpreted with caution since ethnicity might have an
impact on the pharmacokinetic properties of these
drugs. Further studies in larger series with both pregnant
and non-pregnant patients are urgently needed to study
the pharmacokinetics in this vulnerable group.
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